Absci Corporation ABSI 深 沪
已收盘 02-06 16:00:00 美东时间
2.695
+0.165
+6.52%
华盛通- 最 高2.73
- 今 开2.62
- 成交量 374.77万股
- 最 低 2.53
- 昨 收 2.53
- 总市值 4.05亿
- 52周最高 6.33
- 市盈率 静 --
- 换手率 2.49%
- 52周最低 2.01
- 委 比 -81.84%
- 总股本 1.50亿
- 历史最高 31.53
- 量 比 0.94
- 振 幅 7.91%
- 历史最低 1.1111
- 每 手 1
- 风险率 0.67%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多H.B. Fuller, Caledonia Mining And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around...
01-15 21:06
Absci Showcases Generative AI Drug Platform and Pipeline
AbSci ( ($ABSI) ) just unveiled an announcement. On January 14, 2026, Absci Cor...
01-15 06:50
美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
2025-12-19 10:15
美股大行评级 | 博通、Lululemon获10逾家大行上调目标价；好市多、RH遭大行下调目标价
今日重点评级关注：杰富瑞：维持ImmunityBio Inc Ordinary Shares"买入"评级，目标价从8美元升至9美元；B. Riley证券：维持WAVE Life Sciences"买入"评级，目标价从19美元升至37美元
2025-12-15 15:30
Needham Reiterates Buy on Absci, Maintains $7 Price Target
Needham analyst Gil Blum reiterates Absci (NASDAQ:ABSI) with a Buy and maintains $7 price target.
2025-12-12 19:41
Absci Unveils Preclinical Data Showing AI‑Designed Antibody ABS‑201 Stimulates Hair Growth; Findings Presented At ABS‑201 KOL Seminar
Inhibiting prolactin receptor (PRLR) signaling with the ABS-201 anti-PRLR antibody promotes human hair follicle growth ex vivoHuman ex vivo data validate ABS-201's potential to reverse follicular miniaturization and
2025-12-11 21:15
Absci Doses Participants In Phase 1/2a HEADLINE Trial Of ABS-201
Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced that the first healthy volunteers have been dosed in the Phase 1/2a
2025-12-04 21:07
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
2025-11-14 10:43
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Mersana Therapeutics (NASDAQ:MRSN) stock increased by 208.1% to $27.33...
2025-11-13 20:06
Needham Maintains Buy on Absci, Lowers Price Target to $7
Needham analyst Gil Blum maintains Absci (NASDAQ:ABSI) with a Buy and lowers the price target from $8 to $7.
2025-11-13 18:46
